玩股撇步(動畫小學堂)  

  • 理想的成長型公司, 本業EPS的成長幅度會大於營收的成長幅度
  • 營收到某個數字後, 本業EPS呈現不成比例的增加, 有可能是規模經濟的效應
  • 如果是有淡旺季的公司, 是否有淡季不淡, 旺季更旺的情況
  • 漲很多的股票要留意 EPS 較上季是否有大幅衰退的情況
  • 如果EPS衰退,要觀察同業是不是有一樣的狀況
  • 要留意增資減資和公司債對股本及EPS的影響
成長能力-近8季
加權平均股數 QoQ YoYEPS QoQ YoY本業EPS QoQ YoY累計EPS QoQ YoY營收 QoQ YoY毛利率(%) QoQ YoY營業利益率 QoQ YoY稅後淨利率 QoQ YoY營業利益 QoQ YoY稅後淨利 QoQ YoY稅前淨利率(%) QoQ YoY稅後淨利率(%) QoQ YoY兩季平均(YOY)營收成長率(%)兩季平均(YOY)EPS成長率(%)兩季平均(YOY)本業EPS成長率(%)
26Q1 (8)440.00.0-0.3153.0318.42-0.1865.3843.75-0.3181.9818.420.395.41-2.534.8562.47.26-28.6061.6131.35-38.7859.2617.51-0.1160.7135.29-0.1451.7217.65-43.1052.4714.43-38.7859.2617.510.14-23.481.44
25Q4 (7)440.00.0-0.66-100.00.0-0.52-62.5-8.33-1.72-62.26-129.330.37-5.13-11.921.46-44.25-63.27-74.50-77.89-73.74-95.19-126.53-37.06-0.28-75.0-55.56-0.29-93.330.0-90.68-108.41-45.32-95.19-126.53-37.06-2.56-47.15-159.03
25Q3 (6)440.00.0-0.335.71-560.0-0.32-255.56-357.14-1.06-45.21-1077.780.390.0-30.3638.4941.7717.35-41.88-14.08-544.31-42.0226.03-1077.03-0.16-14.29-300.0-0.150.0-650.0-43.5133.1-948.43-42.0226.03-1077.03-1.256.80-91.84
25Q2 (5)440.00.0-0.357.89-488.89-0.0971.88-28.57-0.73-92.11-1725.00.39-2.5-35.027.15-16.443.11-36.7111.88-479.02-56.81-20.85-1186.23-0.1417.65-250.0-0.1511.76-475.0-65.04-29.12-1259.36-56.81-20.85-1186.23--0.00
25Q1 (4)440.00.0-0.3842.420.0-0.3233.330.0-0.3849.330.00.4-4.760.032.49-44.390.0-41.662.850.0-47.0132.310.0-0.175.560.0-0.1741.380.0-50.3719.280.0-47.0132.310.0--0.00
24Q4 (3)440.00.0-0.66-1220.00.0-0.48-585.710.0-0.75-733.330.00.42-25.00.058.4278.110.0-42.88-559.690.0-69.45-1845.380.0-0.18-350.00.0-0.29-1350.00.0-62.40-1403.610.0-69.45-1845.380.0--0.00
24Q3 (2)440.00.0-0.05-155.560.0-0.070.00.0-0.09-125.00.00.56-6.670.032.8024.570.0-6.50-2.520.0-3.57-168.260.0-0.040.00.0-0.02-150.00.0-4.15-173.980.0-3.57-168.260.0--0.00
24Q2 (1)440.00.00.090.00.0-0.070.00.0-0.040.00.00.60.00.026.330.00.0-6.340.00.05.230.00.0-0.040.00.00.040.00.05.610.00.05.230.00.0--0.00
年/月營收月增率(%)去年同期年增率(%)累計營收累計營收年增率(%)近三月累計營收存貨銷售比自結稅前EPS自結稅前累計EPS備註(年增率變動50%需說明原因)
2026/40.153.35-6.040.54-2.350.37N/A-
2026/30.1479.031.930.39-0.890.390.23-
2026/20.08-53.26-62.220.25-13.20.380.24藥品收入減少及IC設計收入退出
2026/10.1729.2120.520.17120.520.430.21藥品收入與鍍膜加工收入增加
2025/120.138.12-8.181.54-20.940.370.6-
2025/110.126.69-23.391.41-21.950.380.58-
2025/100.11-19.77-3.581.29-21.810.390.56-
2025/90.147.86-32.271.18-23.230.390.74-
2025/80.1313.78-11.611.03-21.780.350.82-
2025/70.1211.75-40.920.9-23.090.350.84-
2025/60.1-17.33-51.930.78-19.480.390.75係因本月子公司營收較去年同期減少所致
2025/50.13-19.85-37.720.68-10.20.390.74-
2025/40.1645.12-15.060.55-0.170.480.61-
2025/30.11-48.74-40.780.47.260.40.63-
2025/20.21172.83324.410.2954.190.430.58因本期收入及合併子公司收入較去年同期增加,故本月收入較去年同期增加
2025/10.08-46.2-43.660.08-43.660.380.66-
2024/120.14-9.79-25.681.95-15.470.420.54-
2024/110.1634.29-23.861.81-14.540.490.47-
2024/100.12-43.65-8.721.65-13.510.480.48-
2024/90.2140.772.951.53-13.860.560.38-
2024/80.15-23.94-31.891.32-16.050.560.37-
2024/70.2-9.079.441.17-13.480.620.34-
2024/60.227.161.810.97-17.00.60.35因本公司本月訂單增加及子公司收入增加,故比去年同期收入增加.
2024/50.29.3-18.360.76-27.140.570.37-
2024/40.181.18-25.070.56-29.890.420.5-
2024/30.18267.32-38.20.37-32.080.37N/A-
2024/20.05-63.78-74.330.19-24.80.38N/A因遇春節連假,交易日減少,故收入比去年同期減少
2024/10.14-29.03149.690.14149.690.54N/A因本期增加合併子公司營收,故比去年同期增加
2023/120.19-7.58133.72.31171.360.53N/A因本期增加合併子公司營收,故比去年同期增加
2023/110.2160.99329.932.12175.420.54N/A因本期增加合併子公司營收,故比去年同期增加
2023/100.13-36.43135.831.91164.960.55N/A因本期增加合併子公司營收,故比去年同期增加
2023/90.2-6.86315.881.78167.380.6N/A因本期增加合併子公司營收,故比去年同期增加
2023/80.2222.2180.061.57155.50.53N/A因本期增加合併子公司營收,故比去年同期增加
2023/70.1834.4320.461.35151.910.56N/A因本期增加合併子公司營收,故比去年同期增加
2023/60.13-45.9644.221.17202.540.63N/A因本期增加合併子公司營收,故比去年同期增加
2023/50.250.32191.261.04252.340.79N/A因本期增加合併子公司營收,故比去年同期增加
2023/40.25-16.54551.570.79277.080.74N/A因本期增加合併子公司營收,故比去年同期增加
2023/30.352.55423.330.54216.630.54N/A因本期增加合併子公司營收,故比去年用期增加
2023/20.19252.32267.620.25115.490.33N/A因本期增加合併子公司營收,故比去年同期增加
2023/10.06-33.57-12.320.06-12.320.19N/A-
2022/120.0870.0-12.270.85-17.960.19N/A-
2022/110.05-11.683.960.77-18.530.15N/A-
2022/100.0612.08-38.70.72-19.70.18N/A-
2022/90.05-37.28-4.70.66-17.580.28N/A-
2022/80.08-47.43-0.880.62-18.460.32N/A-
2022/70.1560.9443.290.54-20.520.33N/A-
2022/60.099.12-38.350.39-32.160.22N/A-
2022/50.09124.43-20.770.29-29.940.18N/A-
2022/40.04-32.97-59.390.21-33.080.15N/A因疫情影響,進口藥物交期延宕所致
2022/30.067.16-37.630.17-21.950.17N/A-
2022/20.05-15.97-13.790.12-11.00.21N/A-
2022/10.06-33.53-8.520.06-8.520.2N/A-
2021/120.09101.47-31.411.04-24.690.23N/A-
2021/110.05-47.93-56.920.94-23.940.19N/A因減少合併子公司故本月營收較同期減少
2021/100.0974.25-27.490.9-20.770.22N/A-
2021/90.05-34.76-54.660.81-19.940.24N/A因減少合併子公司故本月營收較同期減少
2021/80.08-24.0-42.130.76-15.510.33N/A-
2021/70.1-30.76-24.150.68-10.70.36N/A-
2021/60.1540.2560.170.57-7.790.0N/A本月營收:西藥3,743;試劑8,630;租金收入1,034;售電收入697;其他951
2021/50.1115.03-31.430.42-19.940.0N/A-
成長能力-近5年
加權平均股數 YoYEPS YoY本業EPS YoY營收 YoY毛利率(%) YoY營業利益率 YoY稅後淨利率 YoY營業利益 YoY稅前淨利 YoY稅後淨利 YoY
2025 (5)440.0-1.720-1.2501.55-20.5130.02-15.25-48.370-59.780-0.750-0.960-0.760
2024 (4)440.0-0.750-0.8601.95-15.5835.427.43-18.150-17.030-0.350-0.310-0.330
2023 (3)444.76-1.8100.5002.31171.7632.97-31.18-3.350-48.190-0.080-1.10-0.80
2022 (2)4235.480.03-97.17-0.6400.85-18.2747.91-7.37-27.9601.50-95.31-0.2400.05-85.290.01-96.88
2021 (1)316.91.060-0.0201.04-24.6451.7201.63031.9800.0200.3400.320

財務分析相關資訊

免責聲明

本網站所有資料僅供參考,如使用者依本資料交易發生交易損失需自行負責,本網站對資料內容錯誤﹑更新延誤不負任何責任。